Day: April 18, 2023

DALLAS, TX, April 18, 2023 (GLOBE NEWSWIRE) — GEX Management Inc. (OTC: GXXM), a leading management consulting company, announced exceptional financial results for the fiscal year ended 2022, with $2.3 million in gross reported revenue, a 76% increase compared to the $1.3 million revenue reported in 2021. CEO Sri Vanamali attributed the success to the strong growth delivered by both the company’s strategy and technology consulting divisions. “Our strategy consulting team has provided clients with customized solutions that have helped them navigate through the enormous complexities of today’s business environment. We have assisted our clients with a spectrum of solutions that include M&A strategy including post-merger integration, risk management, process improvement and strategic planning, and our deep domain...

Yesterday, the new business name of Tallinna Kaubamaja Kinnisvara AS, a subsidiary of Tallinna Kaubamaja Grupp AS, was entered in the commercial register – TKM Kinnisvara AS. The new wording of the articles of association in connection with the change of business name was also approved. Subsequently, it is planned to change the business name and the articles of association of Tartu Kaubamaja Kinnisvara OÜ, another subsidiary in the real estate sector, and the respective new business name shall be TKM Kinnisvara Tartu OÜ.The changes in the business name of Tallinna Kaubamaja Kinnisvara AS and Tartu Kaubamaja Kinnisvara OÜ will harmonise the business names of the subsidiaries of Tallinna Kaubamaja Grupp AS, which engage in real estate. The subsidiaries which manage the Group’s commercial real estate portfolio have grown steadily and diversified...

Martinsried/Munich, April 18, 2023, Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents preclinical data on MDG1015, a T cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1) combined with the Company’s PD1-41BB switch receptor technology at the AACR Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, Florida. The poster presentation with the title “T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors.” can be found on Medigene’s website at https://medigene.com/science/abstracts/. MDG1015 is a third...

WALTHAM, MA, April 18, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Tecogen Inc. (OTCQX: TGEN) will release Q1 2023 financial results on Thursday, May 11th, 2023. The earnings press release and supplemental earnings call slides will be available on the Company’s website at www.Tecogen.com in the “Investor Relations” section under “Financial Results.” Members of Tecogen’s senior management will hold a conference call and webcast on the same day at 9:30 AM Eastern Time to discuss the Company’s financial performance for Q1 2023. The conference call will be available live via telephone and webcast. To listen to the audio portion, dial (877) 407-7186 within the US and Canada or (201) 689-8052 from other international locations. Participants should ask to be joined to the Tecogen earnings call....

Rehovot, Israel, April 18, 2023 (GLOBE NEWSWIRE) — G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical”), a global leader in next-generation mobile health (mHealth) and digital health, is excited to report that patient enrollment has grown in its home monitoring services by 194% between January and April of 2023, as compared to the same period last year. The increase is due to growing demand for homecare monitoring. As previously announced, in the first quarter of 2023, G Medical signed an agreement with AdventHealth of Central Florida (“AdventHealth”), an operator of 20 hospitals and emergency rooms. AdventHealth experiences on average 5.7 million patient visits per year. G Medical also recently signed an agreement with MiCare Path to integrate MiCare Path’s software platform and visualization...

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced the pricing of its underwritten offering of 2,727,273 shares of its Class A common stock at an offering price of $11.00 per share. The gross proceeds from the offering are expected be $30 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All shares in the offering will be offered by Immuneering. Jefferies, TD Cowen and Guggenheim Securities are acting as the joint book-running managers for the offering. Immuneering intends to use the net proceeds of the offering to advance the preclinical...

NRD Cyber Security, a cybersecurity consulting and technology implementation company, increased its revenue by 13% to €6.08 million in 2022, compared to €5.37 million in 2021. The company’s gross profit in 2022 was €2.98 million, an increase of 27% on the previous year. Operating profits stood at €0.56 million, down 8% from 2021. NRD Cyber Security took over operational control of NRD Bangladesh Ltd at the end of 2021. NRD Cyber Security’s sales revenues in foreign markets amounted to €1.33 million in 2022, which was a 50% on the previous year largely due to sales of NRD Cyber Security’s consulting services and its own brand Natrix and CyberSet products in Egypt, Malawi, Bahamas, and other markets. Sales revenue from the Lithuanian market grew by 6% on the previous year to €4.75 million. In 2022, the company had projects...

– Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave way for dose expansion in specific tumors – – Tumor shrinkage and prolonged stable disease observed in ‘cold’ tumors such as MSS CRC – – Robust safety profile allows repeat dosing, sustained target engagement and Treg depletion to maximize long-term clinical benefit – SAN DIEGO and SUZHOU, China, April 18, 2023 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced interim results from its combination dose escalation studies of the masked, anti-CTLA-4 SAFEbody, ADG126, presented at the AACR Annual Meeting in Orlando, Florida, April 14-19,...